Alvotech Has Settled With Johnson & Johnson For Certain Markets For AVT04, A Biosimilar To Stelara (Ustekinumab), Market Entry Of AVT04 In Canada Is Expected In Q1 2024, With May 2024 For Japan, And Later July 2024 For First European Markets
Benzinga Newsdesk - Feb 15, 2024, 6:38AM